Jessica Francois Whitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jessica Francois Whitt has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alex R. Jones
Department of Medicine, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA
2 shared publications - Amit G. Singal
Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publications - Arjmand R. Mufti
Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA
2 shared publications - Donna M. Evon
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, USA
2 shared publications - Lisa B. VanWagner
Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA
2 shared publications - Madhukar S. Patel
Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX
2 shared publications
Latest Publications
- 12 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Medication adherence and telehealth interventions after liver transplantation: A systematic review and meta-analysis
Medication adherence is critical to long-term graft and patient survival after liver transplantation (LT), yet the effectiveness of adherence-promoting interventions across the post-transplant survivorship continuum remains uncertain. We systematically reviewed interventions to improve medication adherence, including immunosuppressive regimen simplification, pharmacist-led or counseling strategies, behavioral and multicomponent programs, and technology-based interventions. We identified 33 studies: immunosuppressive regimen simplification (n=8), pharmacist-led or counseling strategies (n=6), behavioral or multicomponent programs (n=3), virtual visits/remote monitoring (n=9), and mobile or text-based tools (n=7). In pooled analyses of randomized trials, active interventions improved adherence versus usual care (OR 4.04, 95% CI 1.94–8.41), although heterogeneity was substantial. A higher prevalence of alcohol-associated liver disease was associated with weaker intervention effects. Regimen simplification, especially conversion from twice-daily to once-daily tacrolimus, showed consistent improvement in adherence while maintaining acceptable graft outcomes. Pharmacist-led interventions improved medication knowledge, dosing compliance, and drug monitoring. Telehealth interventions reduced travel burden and, in some studies, early readmissions and hospital stays. Overall, regimen simplification and structured multidisciplinary support appear most effective, but larger longitudinal trials with standardized adherence measures are needed.
- 12 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Medication adherence and telehealth interventions after liver transplantation: A systematic review and meta-analysis
Medication adherence is critical to long-term graft and patient survival after liver transplantation (LT), yet the effectiveness of adherence-promoting interventions across the post-transplant survivorship continuum remains uncertain. We systematically reviewed interventions to improve medication adherence, including immunosuppressive regimen simplification, pharmacist-led or counseling strategies, behavioral and multicomponent programs, and technology-based interventions. We identified 33 studies: immunosuppressive regimen simplification (n=8), pharmacist-led or counseling strategies (n=6), behavioral or multicomponent programs (n=3), virtual visits/remote monitoring (n=9), and mobile or text-based tools (n=7). In pooled analyses of randomized trials, active interventions improved adherence versus usual care (OR 4.04, 95% CI 1.94–8.41), although heterogeneity was substantial. A higher prevalence of alcohol-associated liver disease was associated with weaker intervention effects. Regimen simplification, especially conversion from twice-daily to once-daily tacrolimus, showed consistent improvement in adherence while maintaining acceptable graft outcomes. Pharmacist-led interventions improved medication knowledge, dosing compliance, and drug monitoring. Telehealth interventions reduced travel burden and, in some studies, early readmissions and hospital stays. Overall, regimen simplification and structured multidisciplinary support appear most effective, but larger longitudinal trials with standardized adherence measures are needed.
- Open Access
- 21 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Opioid use after adult liver transplantation: Incidence, high-risk use, and adverse events in a large US cohort
Background: Opioid use contributes to significant morbidity, posing specific risks to liver transplant recipients (LTRs). This study aimed to characterize outpatient opioid use before and after liver transplantation (LT) and identify risk factors for high-risk, incident, and chronic use and related complications. Methods: Adult LTRs were identified from 2006 to 2021 in IQVIA PharMetrics Plus for Academics, a claims database representative of the commercially insured US population. Opioid use was evaluated 30–365 days after LT; high-risk use was defined as >50 morphine milligram equivalents (MMEs) per day or concurrent opioid–benzodiazepine use. Factors associated with use, including high-risk use, were identified using multivariable logistic regression analysis. Landmark analyses assessed the association between outpatient opioid use 30–120 days post-LT and incident adverse events (eg, psychiatric, substance use, chronic pain, fractures/falls, digestive). Results: Among 1338 LTRs, 899 (67.2%) received outpatient opioid prescriptions >30 days post-LT, of whom 553 (41%) had incident use; 122 (13.6%) had high-risk opioid use. Factors significantly associated with high-risk use were female sex, pre-LT opioid use, and psychiatric disorder. Opioid use was significantly associated with increased adverse events 120–365 days post-LT; 59% of LTRs with opioid use within 1 year of LT developed complications compared to 39% of non-opioid users during this window (p<0.001). In adjusted landmark analyses, low/moderate opioid use within 30–120 days post-LT was associated with 1.87 times the hazard of complications compared to no opioid use at 120 days post-LT (95% CI: 1.14–3.07) and high-risk opioid use was associated with 2.87 (95% CI: 1.05–7.85) times the hazard. Conclusions: Post-LT opioid use is associated with increased risk of adverse events. Caution is needed in opioid prescribing beyond the perioperative period, particularly for those with preexisting psychiatric conditions.
- 21 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Open AccessOpioid use after adult liver transplantation: Incidence, high-risk use, and adverse events in a large US cohort
Background: Opioid use contributes to significant morbidity, posing specific risks to liver transplant recipients (LTRs). This study aimed to characterize outpatient opioid use before and after liver transplantation (LT) and identify risk factors for high-risk, incident, and chronic use and related complications. Methods: Adult LTRs were identified from 2006 to 2021 in IQVIA PharMetrics Plus for Academics, a claims database representative of the commercially insured US population. Opioid use was evaluated 30–365 days after LT; high-risk use was defined as >50 morphine milligram equivalents (MMEs) per day or concurrent opioid–benzodiazepine use. Factors associated with use, including high-risk use, were identified using multivariable logistic regression analysis. Landmark analyses assessed the association between outpatient opioid use 30–120 days post-LT and incident adverse events (eg, psychiatric, substance use, chronic pain, fractures/falls, digestive). Results: Among 1338 LTRs, 899 (67.2%) received outpatient opioid prescriptions >30 days post-LT, of whom 553 (41%) had incident use; 122 (13.6%) had high-risk opioid use. Factors significantly associated with high-risk use were female sex, pre-LT opioid use, and psychiatric disorder. Opioid use was significantly associated with increased adverse events 120–365 days post-LT; 59% of LTRs with opioid use within 1 year of LT developed complications compared to 39% of non-opioid users during this window (p<0.001). In adjusted landmark analyses, low/moderate opioid use within 30–120 days post-LT was associated with 1.87 times the hazard of complications compared to no opioid use at 120 days post-LT (95% CI: 1.14–3.07) and high-risk opioid use was associated with 2.87 (95% CI: 1.05–7.85) times the hazard. Conclusions: Post-LT opioid use is associated with increased risk of adverse events. Caution is needed in opioid prescribing beyond the perioperative period, particularly for those with preexisting psychiatric conditions.